[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Indian In Vitro Diagnostics Market Analysis 2018

November 2013 | 68 pages | ID: I6DD394E4FEEN
Kuick Research

US$ 700.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The Indian IVD market is valued at more than US$ 500 Million, and is expected to surpass US$ 1.5 Billion by 2018 growing steady at a CAGR of 20%. This remarkable growth can be attributed to increased healthcare awareness, desire to undergo preventive health checkups, availability of disease specific tests, corporate setups promoting health focus of employees, and drift from manual to semi-automated and automated equipment. Emergence of new concepts like point of care testing, near patient testing, increased automation, hospital laboratory management and customer relationship management have revolutionized this segment and contributed towards providing accurate and precise diagnosis at much faster rates.

Apart from catering to people in the Tier I cities, IVD setups are now eyeing expansion in the Tier II and Tier III cities. This can be attributed to high revenue generating option that lie untapped in these cities clubbed with minimum investment required in order to generate high revenues. These IVD majors tie-up with the existing high reputation laboratory adding value in terms of providing technical help as well as contributing significantly in the advising physicians panel.

“Indian In Vitro Diagnostics Market Analysis 2018” research report by KuicK Research is an intriguing text that gives detailed facts and analysis on latest developments in the Indian In Vitro Diagnostics Market landscape. Report gives comprehensive insight on following issues related to development of In Vitro Diagnostics Market in India:
  • Market Overview
  • Market Segment Analysis by Device & Reagents
  • Emerging Market Trends
  • Market Future Outlook
  • Regulation & Policy Framework
  • Competitive Landscape
1. INDIA IVD MARKET OUTLOOK

1.1 Market Introduction
1.2 Current Market Scenario

2. INDIA IVD MARKET DYNAMICS

2.1 Market Growth Drivers
2.2 Market Restraints

3. IVD MARKET BY DEVICE & REAGENTS

3.1 Immunochemistry
3.2 Biochemistry
3.3 Hematology
3.4 Blood Gas & Electrolyte
3.5 Molecular Diagnostics
3.6 Urinalysis
3.7 Coagulation Analysis
3.8 Microbiology

4. EMERGING MARKET TRENDS

4.1 Rising Lab Automation
4.2 Transition towards Preventive Health Checkups
4.3 Entry of Corporate Chains

5. INDIA IVD MARKET FUTURE OUTLOOK

6. REGULATION & POLICY FRAMEWORK

6.1 Registration of Imported IVD Reagents & Devices
6.2 Registration/ Re-Registration of Notified Medical Devices
6.3 Conducting Clinical Trials of Medical Devices
6.4 Import of Non-Notified Diagnostic Kits
6.5 Import of Notified Diagnostics Kits

7. COMPETITIVE LANDSCAPE

7.1 Abbott Diagnostic
7.2 Agappe Diagnostics
7.3 Accurex Biomedical
7.4 Transasia Bio-Medicals
7.5 Roche Diagnostics

LIST OF FIGURES

Figure 1-1: In Vitro Diagnostic Market (US$ Million), 2012-2018
Figure 1-2: In Vitro Diagnostic Reagents Market (US$ Million), 2012-2018
Figure 1-3: In Vitro Diagnostic Instruments Market (US$ Million), 2012-2018
Figure 1-4: In Vitro Diagnostic Market by Reagent & Instrument (%), 2013 & 2018
Figure 1-5: In Vitro Diagnostic Market by Segment (%), 2013 & 2018
Figure 3-1: Immunochemistry Market (US$ Million), 2012-2018
Figure 3-2: Immunochemistry Instruments Market (US$ Million), 2012-2018
Figure 3-3: Immunochemistry Reagents Market (US$ Million), 2012-2018
Figure 3-4: Immunochemistry Reagents Market by Segment (%), 2013 & 2018
Figure 3-5: Biochemistry Market (US$ Million), 2012-2018
Figure 3-6: Biochemistry Reagents Market (US$ Million), 2012-2018
Figure 3-7: Biochemistry Instruments Market (US$ Million), 2012-2018
Figure 3-8: Biochemistry Instrument Market by Segment (%), 2013 & 2018
Figure 3-9: Hematology Market (US$ Million), 2012-2018
Figure 3-10: Hematology Reagents Market (US$ Million), 2012-2018
Figure 3-11: Hematology Instruments Market (US$ Million), 2012-2018
Figure 3-12: Hematology Instrument Market by Segment (%), 2013 & 2018
Figure 3-13: Blood Gas & Electrolyte Market (US$ Million), 2012-2018
Figure 3-14: Blood Gas & Electrolyte Reagents Market (US$ Million), 2012-2018
Figure 3-15: Blood Gas & Electrolyte Analyzers Market (US$ Million), 2012-2018
Figure 3-16: Molecular Diagnostic Market (US$ Million), 2012-2018
Figure 3-17: Molecular Diagnostic Reagents Market (US$ Million), 2012-2018
Figure 3-18: Molecular Diagnostic Instruments Market (US$ Million), 2012-2018
Figure 3-19: Molecular Diagnostic Reagent Market by Segment (%), 2013 & 2018
Figure 3-20: Urinalysis Market (US$ Million), 2012-2018
Figure 3-21: Urinalysis Reagents Market (US$ Million), 2012-2018
Figure 3-22: Urinalysis Instruments Market (US$ Million), 2012-2018
Figure 3-23: Urinalysis Instruments Market by Segment (%), 2013 & 2018
Figure 3-24: Coagulation Market (US$ Million), 2012-2018
Figure 3-25: Coagulation Reagents Market (US$ Million), 2012-2018
Figure 3-26: Coagulation Instruments Market (US$ Million), 2012-2018
Figure 3-27: Microbiology Market (US$ Million), 2012-2018
Figure 3-28: Microbiology Reagents Market (US$ Million), 2012-2018
Figure 3-29: Microbiology Instruments Market (US$ Million), 2012-2018

The Indian immunochemistry instruments and reagents market was valued at US$ xxx Million in 2013, reflecting a xx% increase over 2012. Further subdivisions like ELISA kits and rapid tests contributed additional US$ xx Million and US$ xx Million respectively. The third and the most important segment of reagents, accounted for US$ xx Million. Offlate this segment of IVD seems to be the one showing exponential growth and being the biggest revenue generator for the IVD market. The demand for these tests has grown in the recent years and is still expected to grow manifolds. Primary growth drivers include increasing incidence of infectious diseases, ability to deliver results quicker with the fast Turn Around Time (TAT) and constant innovations in order to keep up with the changing disease patterns.

The increasing prevalence of infectious diseases, cardiac disorders, diabetics, and hronic diseases like autoimmunity and allergy coupled with increase in elderly population has been the major reason contributing to the upsurge. Since the tests are very specific and effective in diagnosing the biomarkers, more and more physicians are prescribing these tests leading to focused development by pharmaceutical companies.

Newer innovative products are constantly in demand diverting most of the financial resources towards development of products that are able to withstand the competition.

Most of the contribution comes from the reagents while around 10% being contributed by instruments. Recent trends like rapid tests and growth of completely new and separate segment called point of care tests have led to the outstanding growth figures and contributed significantly in revenue generation. Though the concept of companion diagnostics is still in nascence and it has to overcome scepticism before it finally hits the market in larger scales, demand for immunochemistry reagents and kits have gone up since these companion diagnostics would be based on immunochemistry. With around 500 products in the pipeline and intense research and development activity being carried out by small and major companies, the future looks bright.

The players in the ELISA kits market have been classified nowadays depending on the revenue generated by them into tier I, II and III and have been cited below. While Lilac Medicare and Euroimmun continue to manage a strong hold over the market and generate significant revenues out of Elisa Kits, others like Transasia and Tulip Diagnostics also have secured position close to them.



More Publications